Chemo-Preventative Agents Will Move To New Cancer Office In Fall
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Office of Oncology Drug Products will assume responsibility for all chemo-preventative drug reviews beginning in the fall, Office of New Drugs Director John Jenkins, MD, told reporters July 16
You may also be interested in...
FDA’s Pazdur Tapped For New Oncology Office Director
Oncology division head Pazdur is selected to lead FDA’s new Office of Oncology Drug Products following national search. Pazdur will begin assuming duties of the office May 1; the office will officially launch in July as part of a broader Office of New Drugs reorganization.
CDER Oncology Division Handling Most Cancer Prevention Drugs Ahead Of Reorg
Two approved products – Pfizer’s Celebrex and Axcan’s Photofrin – and 69 INDs were transferred to the Division of Oncology Drug Products, ahead of the creation of an Office of Oncology Drug Products. The transfer excludes biologics and those drugs aimed at reducing the risk of non-melanoma skin cancer.
CDER Oncology Division Handling Most Cancer Prevention Drugs Ahead Of Reorg
Two approved products – Pfizer’s Celebrex and Axcan’s Photofrin – and 69 INDs were transferred to the Division of Oncology Drug Products, ahead of the creation of an Office of Oncology Drug Products. The transfer excludes biologics and those drugs aimed at reducing the risk of non-melanoma skin cancer.